Orchestra BioMed (OBIO) vs Philip Morris International (PM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Philip Morris International (PM) over the past year, gaining 45.3% versus a gain of 18.6%. Over five years, PM leads with a +107.6% price change compared with -33.3% for OBIO. Philip Morris International is the larger company by market cap ($286.93 billion vs $517.9 million), about 554.1 times the size, while Orchestra BioMed is growing revenue faster (+1169.2% vs +7.3%).
Philip Morris International pays a dividend yielding 3.26%, while Orchestra BioMed does not currently pay one. Philip Morris International converts more of its revenue into profit, with a net margin of 27.9% versus -157.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OBIO | PM |
|---|---|---|
| Share price | $6.58 | $184.09 |
| Market cap | $517.88M | $286.93B |
| 1-day change | -6.00% | -1.26% |
| YTD return | +58.55% | +14.77% |
| 1-year return | +45.25% | +18.58% |
| 5-year return | -33.27% | +107.59% |
| P/E ratio (TTM) | — | 26.87 |
| Forward P/E | — | 20.36 |
| EPS (TTM) | $-0.75 | $6.85 |
| Dividend yield | 0.00% | 3.26% |
| Annual dividend | $0.00 | $6.01 |
| Revenue (latest FY) | $33.48M | $40.65B |
| Revenue growth (YoY) | +1169.22% | +7.31% |
| Net income (latest FY) | $-52.70M | $11.35B |
| Gross margin | 99.43% | 67.12% |
| Operating margin | -154.73% | 36.64% |
| Net margin | -157.40% | 27.92% |
| 52-week high | $7.83 | $214.35 |
| 52-week low | $3.46 | $146.35 |
| Distance from 52-week high | -15.91% | -14.12% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +101.98% | +15.54% |
| Average volume | 420.19K | 4.76M |
| Shares outstanding | 78.70M | 1.56B |
| Employees | 86 | 84,900 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Philip Morris International is about 554.1 times larger than Orchestra BioMed by market value ($286.93B vs $517.88M).
- OBIO has outperformed PM by 26.7 percentage points over the past year.
- Philip Morris International offers a meaningfully higher dividend yield (3.26% vs 0.00%).
- Philip Morris International is more profitable, keeping 27.9 cents of every revenue dollar as net income versus -157.4 cents for Orchestra BioMed.
- Orchestra BioMed grew revenue faster in its latest fiscal year (+1169.22% vs +7.31%).
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
About Philip Morris International
PM stock →Philip Morris International Inc. operates as a tobacco company.
Health Care · Medicinal Chemicals and Botanical Products · 84,900 employees
OBIO vs PM FAQ
Which is bigger, Orchestra BioMed or Philip Morris International?
Philip Morris International (PM) is larger, with a market capitalization of $286.93B compared with $517.88M for Orchestra BioMed (OBIO).
Which stock has performed better over the past year, OBIO or PM?
OBIO returned +45.25% over the past 12 months, compared with +18.58% for PM (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Orchestra BioMed or Philip Morris International?
Philip Morris International pays a dividend yielding 3.26%, while Orchestra BioMed does not currently pay a regular dividend.
Are Orchestra BioMed and Philip Morris International in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.